TABLE 2.
Characteristics of pediatric AML patients who underwent ISD‐SCT or HID‐SCT in the subgroup for patients in CR1 with known cytogenetics
| Characteristic | ISD‐SCT (n = 14) | HID‐SCT (n = 44) | P value |
|---|---|---|---|
| Age of recipients (range, years) | 14 (4‐16) | 12 (2‐16) | 0.741 |
| Sex of recipients | 0.380 | ||
| Male | 8 (57.1%) | 21 (47.7%) | |
| Female | 6 (42.9%) | 23 (52.2%) | |
| WBC at diagnosis (range, × 109/L) | 19.9 (2.1‐55.7) | 25.1 (1.0‐404.0) | 0.357 |
| Time from diagnosis to SCT (range, months) | 4.0(1.0‐31.0) | 5.2 (1.0‐60.0) | 0.440 |
| Cytogenetic risk | 0.172 | ||
| Favorable | 2 (14.3%) | 3 (6.8%) | |
| Intermediate | 6 (42.9%) | 31 (70.5%) | |
| Adverse | 6 (42.9%) | 10 (22.7%) | |
| Resistant to first cycle of chemotherapy | 5 (35.7%) | 19 (43.2%) | 0.547 |
| Number of chemotherapy cycles (range) | 4.5 (1‐16) | 4 (2‐20) | 0.525 |
| ABO incompatibility | 0.026 | ||
| Match | 13 (92.8%) | 22 (50.0%) | |
| Minor mismatch | 0 | 5 (11.4%) | |
| Major mismatch | 0 | 14 (31.8%) | |
| Bidirectional mismatch | 1 (7.1%) | 3 (6.8%) | |
| Age of donors (range, years) | 16 (10‐31) | 38.5 (11‐52) | 0.002 |
| Sex of donors | 0.540 | ||
| Male | 6 (42.9%) | 25 (56.8%) | |
| Female | 8 (57.1%) | 19(43.2%) | |
| Graft source | 0.086 | ||
| BM+PBSC | 10 (71.4%) | 40 (90.9%) | |
| PB | 4 (28.6%) | 4 (9.1%) | |
| Median MNC (range, × 108/kg) | 9.01 (5.43‐15.82) | 8.95 (3.19‐16.66) | 0.759 |
| Median CD34 (range, × 106/kg) | 3.12 (1.10‐6.20) | 3.09 (0.52‐10.00) | 0.759 |
AML, acute myeloid leukemia; SCT, stem cell transplantation; CR, complete remission; ISD, identical sibling donor; HID, haploidentical donor; WBC, white blood cell; BM, bone marrow; PBSC, peripheral blood stem cell; MNC, mononuclear cell.